Briquilimab

DRUG9 trials

Sponsors

Jasper Therapeutics Inc., National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Jasper Therapeutics, Inc.

Conditions

Allergic AsthmaBeta ThalassemiaChronic Inducible UrticariaChronic Spontaneous UrticariaChronic UrticariaGATA2ImmunodeficiencySickle Cell Anemia

Phase 1

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Active, not recruitingNCT05357482

National Heart, Lung, and Blood Institute (NHLBI)Beta Thalassemia, Sickle Cell Anemia

Start: 2022-05-12End: 2027-01-31Updated: 2026-03-12

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

Active, not recruitingNCT06162728

Jasper Therapeutics, Inc.Chronic Spontaneous Urticaria

Start: 2023-11-29End: 2026-10-31Updated: 2026-01-22

A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Sympomatic Despite Treatment with H1 Antihistamines and/or Omalizumab, or who Cannot Tolerate Omalizumab

Active, not recruitingCTIS2023-505446-25-00

Jasper Therapeutics Inc.Chronic Spontaneous Urticaria

Start: 2024-03-20Target: 31Updated: 2025-11-04

A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihistamines

CompletedCTIS2023-507534-24-00

Jasper Therapeutics Inc.Chronic Inducible Urticaria

Start: 2024-03-06End: 2025-07-31Target: 20Updated: 2024-09-23

A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

TerminatedNCT06353971

Jasper Therapeutics, Inc.Chronic Inducible Urticaria

Start: 2024-03-18End: 2025-07-31Updated: 2025-10-08

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

TerminatedNCT06592768

Jasper Therapeutics, Inc.Allergic Asthma

Start: 2024-11-26End: 2025-08-11Updated: 2025-09-16

Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Active, not recruitingNCT05907746

National Cancer Institute (NCI)GATA2, Immunodeficiency

Start: 2023-11-29End: 2028-07-31Updated: 2025-11-03

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Active, not recruitingNCT06736262

Jasper Therapeutics, Inc.Urticaria Chronic

Start: 2024-11-26End: 2026-09-30Updated: 2026-02-23

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsored Chronic Urticaria Trials

RecruitingCTIS2024-517830-17-00

Jasper Therapeutics Inc.Chronic Urticaria

Start: 2025-03-14Target: 45Updated: 2025-12-22